Clinical Trial Detail

NCT ID NCT03647488
Title Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib + Spartalizumab

Docetaxel

Age Groups: adult senior

Additional content available in CKB BOOST